Jeffrey Tran, MD
Ophthalmology · Suwanee, GANPI 1285098533
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.4%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Bausch & Lomb Americas Inc. accounts for 75.7% of it on its own, with 25 other manufacturers making up the rest. 2025 is the largest year on record at $86,008, more than ten times the $864 reported in 2019. Among ophthalmology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 458 payments — averaging $326.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$113K
- Sun Pharmaceutical Industries Inc.$22K
- AbbVie$3K
- Glaukos Corporation$3K
- Alcon$2K
- NEW World Medical,inc.$2K
- plus $4K from 20 others
What the payments were for
- Consulting fees$28,16319%
- Speaking & faculty fees$87,30058%
- Travel & lodging$13,9879%
- Food & beverage$19,92813%
- Education$180%
- Entertainment$2170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 220 | $113,262 |
| Sun Pharmaceutical Industries Inc. | 42 | $21,512 |
| AbbVie(2 entities) | 36 | $3,489 |
| Glaukos Corporation | 28 | $2,641 |
| Alcon | 36 | $2,495 |
| NEW World Medical,inc. | 12 | $1,755 |
| Oyster Point Pharma, Inc. | 25 | $915 |
| Harrow Eye, LLC | 12 | $565 |
| Johnson & Johnson Surgical Vision, Inc. | 10 | $512 |
| Aerie Pharmaceuticals, Inc. | 3 | $413 |
| Nova Eye, Inc. | 2 | $389 |
| Eyevance Pharmaceuticals LLC | 5 | $360 |
| Carl Zeiss Meditec USA, Inc. | 1 | $190 |
| Abiomed | 3 | $147 |
| Ivantis, Inc | 2 | $131 |
| Amgen | 1 | $120 |
| Medtronic | 1 | $120 |
| Iridex Corporation | 1 | $120 |
| Novartis | 6 | $114 |
| Biotissue Holdings Inc. | 2 | $77 |
| Tarsus Pharmaceuticals, Inc. | 3 | $76 |
| Sight Sciences, Inc. | 1 | $75 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $69 |
| Tearlab Corp | 1 | $27 |
| Rxsight Inc | 1 | $23 |
| Kala Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIIDRA$102,135
- MIEBO$100,388
- CEQUA$20,258
- VYZULTA$2,664
- Ahmed Glaucoma Valve$1,253
- Kahook Dual Blade$1,253
- Rocklatan$997
- Clearpath$624
- Streamline$624
- BLINK NUTRITEARS$575
- iStent inject Trabecular Micro-Bypass Stent System$541
- Photrexa$532
- Centurion$517
- Rhopressa$436
- Streamline Surgical System$415
- Via360$377
- iStent inject W$350
- Tecnis IOL$289
- RADIUS$280
- TYRVAYA$267
How this compares
$149,613 in reported general payments places this provider in the 95th percentile of 481 ophthalmology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 241 | $288,112 |
| CequaCyclosporine | 170 | $238,588 |
| TyrvayaVarenicline Tartrate | 125 | $142,830 |
| RestasisCyclosporine | 78 | $56,132 |
| VyzultaLatanoprostene Bunod | 62 | $30,293 |
| MieboPerfluorohexyloctane/Pf | 29 | $29,207 |
| LumiganBimatoprost | 16 | $14,113 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 40 | $11,990 |
| ProlensaBromfenac Sodium | 32 | $10,977 |
| Cyclosporine | 21 | $10,909 |
| Lotemax SmLoteprednol Etabonate | 38 | $9,333 |
| VevyeCyclosporine | 12 | $8,659 |
| BesivanceBesifloxacin Hcl | 33 | $7,219 |
| RhopressaNetarsudil Mesylate | 12 | $4,876 |
| Prednisolone Acetate | 41 | $1,309 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $113,262 | $347,613332 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $21,512 | $238,588170 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $915 | $142,830125 claims |
| AbbVieRestasis, Lumigan | $3,489 | $70,24594 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm, Besivance | $69 | $27,528103 claims |
| AlconSimbrinza | $2,495 | $11,99040 claims |
| Harrow Eye, LLCVevye | $565 | $8,65912 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $413 | $4,87612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 481 ophthalmology providers in Georgia.
Other ophthalmology in Suwanee
- Gagan SawhneyAtlanta$582K
- Lawrence WoodardAtlanta$578K
- Stephanie VanderveldtAtlanta$384K
- Steven YehAtlanta$289K
- Jack ChapmanGainesville$244K
- Gregory LeeCumming$214K
- Puneet PandaMarietta$185K
- Evan SchoenbergAtlanta$130K
- Niraj DesaiCumming$129K
- Robert StultingAtlanta$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.